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ABSTRACT:  
Treatment of multiple sclerosis (MS) is challenging: disease-modifying treatments (DMTs) must both limit unwanted immune 
responses associated with disease initiation and propagation (as T and B lymphocytes are critical cellular mediators in the 
pathophysiology of relapsing MS), and also have minimal adverse impact on normal protective immune responses. There are a 
number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational 
agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in 
relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. 
Teriflunomide selectively and reversibly inhibits dihydro-orotate dehydrogenase, a key mitochondrial enzyme in the de novo 
pyrimidine synthesis pathway, leading to a reduction in proliferation of activated T and B lymphocytes without causing cell death. 
Results from animal experiments modelling the immune activation implicated in MS demonstrate reductions in disease symptoms 
with teriflunomide treatment, accompanied by reduced central nervous system lymphocyte infiltration, reduced axonal loss, and 
preserved neurological functioning. Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of 
relapsing forms of multiple sclerosis (MS) in September 2012. Its primary mode of action is inhibition of dihydroorotate 
dehydrogenase which inhibits the proliferation of activated T cells, but it also has a number of other actions that may be important 
contributors to its efficacy in MS. This review will summarize teriflunomide’s historical development, clinical pharmacology, 
studies in animals, clinical trials, and safety data, and will end with a discussion of the role of teriflunomide in MS in the context 
of existing treatment options. 
Keywords: teriflunomide, multiple sclerosis, clinical trials, disease-modifying treatments. 
DOI: http://dx.doi.org/10.22270/jddt.v6i5.1303            URI: http://jddtonline.info/index.php/jddt/article/view/1303 
 
INTRODUCTION: 
Teriflunomide is an effective and safe oral treatment 
option for relapsing MS. It can be used as monotherapy 
or added to interferon or glatiramer acetate. 
Teriflunomide reduces the rate of relapse and may slow 
disease progression. The advantages of this drug are the 
convenience of oral administration and good 
tolerability. The disadvantages are the lack of long-term 
safety data and data on the benefit of combination 
therapy
1
. 
Teriflunomide is the principal active metabolite of 
leflunomide, which has been licensed for use in the 
treatment of rheumatoid arthritis (RA) for over a 
decade.
2
Leflunomide was discovered in the 1980s 
during a chemical compound-screening process 
intended to identify agricultural pesticides, and was 
inadvertently found to have both anti-inflammatory and 
immunosuppressive propertiesand was thus developed 
for use in RA. Due to its efficacy, safety, and 
tolerability in RA, leflunomide was later tested in 
animal models of other inflammatory disorders, 
including experimental autoimmune encephalitis, the 
animal model of MS. Upon oral ingestion, leflunomide 
is rapidly converted into its primary active metabolite, 
teriflunomide. Since teriflunomide is able to avoid the 
first-pass metabolism that leflunomide undergoes, it has 
become the focus of development in MS 
patients
3
.Teriflunomide may cause major birth defects 
or fetal death if used during pregnancy. Do not take 
teriflunomide if you are pregnant. Do not take it if you 
may become pregnant and are not using an effective 
form of birth control. You must make sure you are not 
pregnant before you start teriflunomide. Do not become 
pregnant while you take teriflunomide or for as long as 
any medicine remains in your body after you stop 
treatment. Teriflunomide may stay in the body for as 
long as 2 years after you stop it. Women who may 
become pregnant must use effective birth control while 
they take teriflunomide and for as long as any medicine 
remains in the body
4-5
. 
Additionally, teriflunomide has been shown in in 
vitroand in animal studies to inhibit tyrosine kinases, 
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nuclear factor-κB, cyclooxegenase-2, and other 
proteins, but the drug’s binding affinity for these targets 
is much lower than its affinity for DHODH.
6
As a result, 
the mechanisms of teriflunomide appear to be 
concentration dependent. At drug concentrations 
achievable with therapeutic doses of teriflunomide, it is 
likely that DHODH inhibition is the predominant 
mechanism.
7
 
Protein-tyrosine kinase inhibitors have been useful in 
defining the role of these enzymes in signal 
transduction events. Herbimycin A, a benzoquinonoid 
ansamycin antibiotic, increases the turnover of p56
lck
 
and p59
fyn
, which in turn decreases tyrosine kinase 
activity in human T lymphocytes, and thus impairs 
signal transduction by the TCR complex. Tyrosine 
phosphorylation, PLC-γ1 activity, phosphatidylinositol 
4, 5-bisphosphate hydrolysis, and [Ca
2+
] mobilization, 
as well as the expression of distal markers of T cell 
activation, such as interleukin-2 (IL-2) and IL-2 
receptor (IL-2R), are all inhibited by herbimycin A.
8
 
Genistein, a natural isoflavone, also inhibits tyrosine 
phosphorylation of PLC-γ1 and other substrates, 
although it is less effective than herbimycin A and has 
only marginal effects on the generation of inositol 
1,4,5-trisphosphate and Ca
2+
 mobilization. However, 
genistein still efficiently blocks IL-2 production and IL-
2 receptor expression. Both herbimycin A and genistein 
are capable of blocking proliferation of T cells 
stimulated by phytohemagglutinin or by anti-TCR 
antibody, but neither has yet been tested in any in vivo 
animal models for immunosuppression.
9 
 
Table 1: Food and Drug Administration–Approved Agents for Relapsing Forms of Multiple Sclerosis. 
Drug (Brand Name) Dose Route of 
Administration 
Comments 
Dimethyl fumarate, 
delayed release 
(Tecfidera) 
240 mg twice 
daily 
Oral 
 
30% decrease in lymphocytes during therapy, flushing 
common 
 
Fingolimod (Gilenya) 0.5 mg once 
daily 
Oral 
 
 
Requires extensive monitoring includingvaricella 
zoster immunity evaluation, pulse, blood pressure, 
ophthalmologyexamination, dermatologic examination 
Glatiramer acetate 
(Copaxone) 
 
20 mg once 
daily 
 
 
Subcutaneous 
 
 
First-line therapy,  skin reactions common 
 
 Natalizumab (Tysabri) 
 
 
300 mg every 
4 weeks 
 
Intravenous 
 
 
Requires registration of patient, pharmacy, 
andprescriber before use because of concerns 
ofprogressive multifocal leukoencephalopathy Teriflunomide 
(Aubagio) 
 
7 mg or 14 
mg once daily 
Oral 
 
Hepatotoxicity and teratogenicity risk 
 
 
ACTIVE SUBSTANCE:  
The chemical name of teriflunomide is (Z)-2-Cyano-3-
hydroxy-but-2-enoic acid-(4-trifluoromethylphenyl) 
amide with molecular formula C
12
H
9
F
3
N
2
O
2 
and 
relative molecular mass 270.2 g/mol. Its structural 
formula is shown below:  
 
Figure 1: Structure of Teriflunomide 
Teriflunomide appears as a white to almost white, 
odourless, non-hygroscopic powder. It is a 
biopharmaceutical classification system (BCS) Class 2 
compound, which is practically insoluble in water; 
sparingly soluble in acetone; and slightly soluble in 
ethanol, acetonitrile and methylene chloride.  
Teriflunomide contains no asymmetric centres, 
therefore no enantiomers are possible.  
The presence of polymorphs of teriflunomide has been 
evaluated using DSC and X-ray powder diffraction and 
recrystallization from different solvents and only one 
polymorphic form has been observed. In addition, 
single crystal X-ray diffraction analysis studies have 
demonstrated that teriflunomide in the solid state 
(crystalline phase) is only the Z-isomer.  
The structure of teriflunomide has been elucidated by 
elemental analysis (C, H and N), spectroscopic 
analyses (IR, UV, 
1
H-NMR, 
13
C-NMR,
 15N
-NMR, 
19
F-
NMR and mass spectrometry) and single X-ray 
diffraction analysis. All data are consistent with the 
proposed structure. 
PHARMACOKINETICS: 
Leflunomide is rapidly converted to teriflunomide in 
the gastrointestinal tract wall and/or the liver and the 
pharmacokinetics of the 2 compounds are similar.
10 
The half-life of teriflunomide is more than 2 weeks and 
steady-state serum concentrations are reached in 
approximately 3 months. The concentration–dose 
relationship is linear with doses of 7 to 100 mg. 
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The pharmacokinetic characteristics after single p.o. or 
i.v. administration of teriflunomide were evaluated in 
male mice, rats, rabbits and dogs using formulations 
that were subsequently also analysed in toxicological 
investigations. These results were complemented with 
toxicokinetic data, which document teriflunomide 
pharmacokinetics following repeated dosing. Protein 
binding properties of teriflunomide were investigated 
in vitro. Teriflunomide was maximally absorbed in 
mice, rats, rabbits and dogs within 1 hrs, 6 hrs, 4-8 hrs 
or 1-4 hrs post dose culminating in levels of 36 μg/ml, 
48.4 μg/ml, 25.9 μg/ml or 58.9 μg/ml, respectively. 
Teriflunomide showed almost 100% oral 
bioavailability in mice, rats and dogs, whereas it 
showed clearly lower levels (~66 %) in rabbits. 
Extensive protein binding between 96 and more than 
99 % was determined in animals and man
11
.  
Following repeated oral administration of 
teriflunomide to mice and rats for up to 3 and 6 
months, respectively, systemic exposure generally 
increased linearly with dose. The exposure increased in 
a greater than dose-proportional manner in dogs after 
repeated oral administration for up to 12 months and in 
pregnant rabbits treated orally for up to 7 days. 
Accumulation of teriflunomide was noted in all species 
after repeated doses reaching steady-state after 
approximately 1 month in mice and dogs and after 3 
months in rats. There were no gender differences 
across test species
12-13
. 
CLINICAL PHARMACOLOGY: MECHANISM 
OF ACTION OF TERIFLUNOMIDE 
The precise mechanisms by which teriflunomide exerts 
immunomodulatory effects in MS are incompletely 
understood. Teriflunomide primarily acts as an 
inhibitor of dihydroorotate dehydrogenase (DHODH), 
a key mitochondrial enzyme involved in the de novo 
synthesis of pyrimidines in rapidly proliferating cells. 
By reducing the activity of high-avidity proliferating T 
lymphocytes and B lymphocytes, teriflunomide likely 
attenuates the inflammatory response to autoantigens in 
MS.
14
Of note, DHODH blockade does not affect 
resting or homeostatically proliferating hematopoietic 
cell lines, as pyrimidine pools in these cells can be 
generated through an alternate “salvage pathway,” 
which is independent of the DHODH.As a result, basic 
homeostatic functions of resting and slowly dividing 
cells appear to be preserved, and lymphocytes remain 
available for immune surveillance. Thus, teriflunomide 
can be considered a cytostatic rather than a cytotoxic 
drug to leukocytes. In addition to DNA and RNA 
synthesis, pyrimidines are involved in a myriad of 
cellular functions, including protein and lipid 
glycosylation, phospholipid synthesis, and DNA strand 
repair, together which lead to a variety of downstream 
immunomodulatory effects (Figure 2)
15-17
. 
 
 
 
Figure 2: Cell cycle modulations. Some agents block signal transduction events in the resting G0 phase. Other agents 
interfere with ribonucleotide biosynthesis in the G1 phase. In either case, transition into the DNA replication phase, or 
S phase, of the cell cycle is blocked. NFAT = nuclear factor of activated T cells. 
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Figure 3: Effect of inhibition of de novo pyrimidine synthesis on various mechanisms of activated lymphocytes. 
(Adapted from Herrmann et al.
18
) 
 
TERIFLUNOMIDE IS USED FOR: 
Treating certain forms of multiple sclerosis (MS). It 
may also be used for other conditions as determined by 
your doctor. Teriflunomide is a pyrimidine synthesis 
inhibitor. Exactly how teriflunomide works to treat MS 
is not known. 
BEFORE USING TERIFLUNOMIDE: 
Some medical conditions may interact with 
teriflunomide. Tell your doctor or pharmacist if you 
have any medical conditions, especially if any of the 
following apply to you: 
 if you are pregnant, planning to become pregnant, 
or are breast-feeding 
 if you are taking any prescription or 
nonprescription medicine, herbal preparation, or 
dietary supplement 
 if you have allergies to medicines, foods, or other 
substances 
 if you have a weakened immune system, a fever or 
an infection, a history of an infection that keeps 
coming back, or you have recently received or are 
scheduled to receive a vaccination 
 if you have a history of lung or breathing 
problems, tuberculosis (TB) or a positive TB test, 
high blood pressure, blood or bone marrow 
problems, diabetes, liver problems, or abnormal 
liver function tests, or if you drink alcoholic 
beverages 
 if you have unusual numbness or tingling in your 
hands or feet that is different from your MS 
symptoms, or if you have had serious skin 
problems from taking other medicine 
 if you have or have had a history of kidney 
problems or you are on dialysis 
 if you take or have recently taken other medicine 
for MS, medicine to treat cancer, or any other 
medicine that may suppress your immune system 
 if you take cholestyramine.19-21 
DRUG- INTERACTION: 
Some Medicines may interact with teriflunomide. Tell 
your health care provider if you are taking any other 
medicines, especially any of the following: 
 Leflunomide because it may increase the risk of 
teriflunomide's side effects. 
 Atorvastatin, cefaclor, cimetidine, ciprofloxacin, 
furosemide, ketoprofen, nateglinide, oral 
contraceptives (birth control pills), paclitaxel, 
penicillin G, pioglitazone, pravastatin, repaglinide, 
rosiglitazone, rosuvastatin, simvastatin, or 
zidovudine because the risk of their side effects 
may be increased by teriflunomide. 
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 Alosetron, anticoagulants (eg, warfarin), 
duloxetine, theophylline, or tizanidine because 
their effectiveness may be decreased by 
teriflunomide. 
 Methotrexate because the risk of liver problems, 
blood problems, or infection may be increased. 
 Rifampin because it may increase the risk of 
teriflunomide's side effects. 
 Anticoagulants (eg, warfarin) because the risk of 
its side effects, including bleeding, may be 
increased by teriflunomide. 
 Medicines that may suppress the immune system 
because the risk of infection or unusual bruising or 
bleeding may be increased. Ask your doctor if you 
are unsure if any of your medicines may suppress 
the immune system. 
 Medicines that may cause nerve problems, because 
the risk of a certain nerve side effect (burning, 
numbness, or tingling sensation) may be increased. 
Ask your doctor if you are unsure if any of you 
medicines may cause nerve problems. 
 Medicines that may harm the liver (eg, 
acetaminophen, methotrexate, ketoconazole, 
isoniazid, certain medicines for HIV infection) 
because the risk of liver side effects may be 
increased. Ask your doctor if you are unsure if any 
of your medicines might harm the liver.
22
 
HOW TO USE TERIFLUNOMIDE: 
Use teriflunomide as directed by your doctor. Check 
the label on the medicine for exact dosing instructions. 
 Teriflunomide comes with an extra patient 
information sheet called a Medication Guide. Read 
it carefully. Read it again each time you get 
teriflunomide refilled. 
 Take teriflunomide by mouth with or without food. 
 If you miss a dose of teriflunomide, take it as soon 
as possible. If it is almost time for your next dose, 
skip the missed dose and go back to your regular 
dosing schedule. Do not take 2 doses at once.
23
 
CONCLUSION:  
Teriflunomide is an effective and safe oral treatment 
option for relapsing MS. It can be used as monotherapy 
or added to interferon or glatiramer acetate. It reduces 
the rate of relapse and may slow disease progression. 
The advantages of this drug are the convenience of oral 
administration and good tolerability. The disadvantage 
is the lack of long-term safety data and data about the 
benefit of combination therapy. 
For decades, patients with MS and health care 
providersmanaging treatment have awaited oral 
disease-modifying agents. With 3 oral drugs now 
available and more in development, there are several 
treatment options. Teriflunomide also is well tolerated 
and requires less patient monitoring when compared 
with some other treatments for MS such as 
mitoxantrone, natalizumab, and fingolimod. This 
tolerability and patient preference for oral therapy are 
likely reflected in the relatively low discontinuation 
rates.In addition, the long washout period of 
teriflunomide may have implications for the use of 
other immunosuppressive agents in individuals with 
breakthrough disease on this drug, although rapid-
elimination procedures may mitigate this concern. 
Most importantly, as with any novel pharmacological 
agent, post marketing surveillance will be essential in 
more definitively characterizing the long-term safety 
and efficacy of teriflunomide in the treatment of MS in 
the real world. 
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